Discovery of potent SARS-CoV-2 nsp3 macrodomain inhibitors uncovers lack of translation to cellular antiviral response
Lee, A. A.; Amick, I.; Aschenbrenner, J. C.; Barr, H. A.; Benjamin, J.; Brandis, A.; Cohen, G.; Diaz-Tapia, R.; Duberstein, S.; Dixon, J.; Cousins, D.; Fairhead, M.; Fearon, D.; Frick, J.; Gayvert, J.; de Godoy, A. S.; Griffen, E. J.; Huber, K. V. M.; Koekemoer, L.; Lahav, N.; Marples, P. G.; McGovern, B. L.; Mehlman, T.; Robinson, M. C.; Singh, U.; Szommer, T.; Tomlinson, C. W. E.; Vargo, T.; von Delft, F.; Wang, S.; White, K. M.; Williams, E.; Winokan, M.
Show abstract
A strategy for pandemic preparedness is the development of antivirals against a wide set of viral targets with complementary mechanisms of action. SARS-CoV-2 nsp3-mac1 is a viral macrodomain with ADP-ribosylhydrolase activity, which counteracts host immune response. Targeting the virus immunomodulatory functionality offers a differentiated strategy to inhibit SARS-CoV-2 compared to approved therapeutics, which target viral replication directly. Here we report a fragment-based lead generation campaign guided by computational approaches. We discover tool compounds which inhibit nsp3-mac1 activity at low nanomolar concentrations, and with responsive structure-activity relationships, high selectivity, and drug-like properties. Using our inhibitors, we show that inhibition of nsp3-mac1 increases ADP-ribosylation, but surprisingly does not translate to demonstrable antiviral activity in cell culture and iPSC-derived pneumocyte models. Further, no synergistic activity is observed in combination with interferon gamma, a main protease inhibitor, nor a papain-like protease inhibitor. Our results question the extent to which targeting modulation of innate immunity-driven ADP-ribosylation can influence SARS-CoV-2 replication. Moreover, these findings suggest that nsp3-mac1 might not be a suitable target for antiviral therapeutics development.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Post-infection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection 97%
- An influenza A hemagglutinin small-molecule fusion inhibitor identified by a new high-throughput fluorescence polarization screen. 96%
- Iterative computational design and crystallographic screening identifies potent inhibitors targeting the Nsp3 Macrodomain of SARS-CoV-2 96%
Similar papers in this journal
- Screening a library of FDA-approved and bioactive compounds for antiviral activity against SARS-CoV-2 97%
- Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19 96%
- Small-Molecule In Vitro Inhibitors of the Coronavirus Spike - ACE2 Protein-Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2 96%
Similar papers in this journal
- Discovery of compounds that inhibit SARS-CoV-2 Mac1-ADP-ribose binding by high-throughput screening 96%
- The α-dystroglycan N-terminus is a broad-spectrum antiviral agent against SARS-CoV-2 and enveloped viruses 94%
- A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors 94%
Similar papers in this journal
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.